Oncopeptides plans directed share issue of about SEK 100 million
Oncopeptides launched an accelerated bookbuild for a directed share issue of about SEK 100 million to institutional investors. Proceeds earmarked for CMC work, trial-start preparations, and funding the next clinical phase in its glioblastoma program. HealthCap VIII LP signaled interest to subscribe for SEK 10 million.